On September 2, 2026 Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, reported that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use. The patent allowance further expands the Company’s intellectual property portfolio supporting its proprietary CAPTN-3 platform for conditionally activated multispecific antibodies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The newly allowed U.S. patent strengthens protection for the modular architecture underlying CAPTN-3, a platform designed to enable the efficient generation of tri-specific antibodies by exchanging tumor-associated antigen (TAA) binding domains and other functional arms while leveraging a common platform backbone. This flexibility is intended to accelerate the development of new therapeutic candidates across multiple cancer indications.
"This U.S. patent allowance is another important element in the evolution of the CAPTN-3 platform," said Gil Efron, Purple Biotech CEO. "Beyond expanding our intellectual property portfolio, it reinforces protection for the modular design that allows us to rapidly develop new multispecific antibody candidates by incorporating different targeting domains and functional components. As we continue to enhance the platform, we expect to generate additional antibody programs that address a broad range of oncology targets."
The U.S. patent allowance complements Purple Biotech’s growing patent estate and reflects the Company’s strategy of continuously expanding both the capabilities of, and the intellectual property supporting, its conditionally activated multispecific antibody technologies. As the technology evolves, the Company expects to introduce additional antibody candidates built on this adaptable platform.
About the Allowed Patent
The USPTO has issued a Notice of Allowance for U.S. patent application entitled "Precursor Tri-Specific Antibody Constructs and Methods of Use Thereof." The allowed claims cover tri-specific antibody constructs comprising dual TAA binders alongside other features of the CAPTN-3 platform, further strengthening the intellectual property protecting the CAPTN-3 platform, expanding its versatility and its future development and partnering potential. A Notice of Allowance indicates that the USPTO has determined the allowed claims meet the requirements for patentability, subject to payment of the required issue fees.
(Press release, Purple Biotech, SEP 2, 2026, View Source;id=407360&p=2452215&I=1206939-c7Z3G6f3m8 [SID1234670547])